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3 Introduction 
4 
5 
Anti-psychotic medications (such as risperidone, olanzapine, and haloperidol) form an 
7 appropriate, and important, part of the treatment of the distressing symptoms that 
8 characterise and are associated with mental health conditions (such as bipolar disorder and 
9 schizophrenia), including those of adults with learning disabilities. However, anti-psychotic 
10 medication has also been used for people without any mental health diagnosis, to manage 
11 perceived ‘challenging’ and/or illegal behaviour. While this matter has been of long-standing 
12 concern in the UK, and in some other well-resourced countries (de Kuijper et al., 2010; 
14 McGillivray and McCabe, 2004; Matson and Neal, 2008), it has received much greater 
15 attention since the introduction of the government’s Transforming Care agenda  (see 
16 Department of Health, 2012; Glover et al., 2014). Moreover, the focus has now extended 
17 beyond anti-psychotics to the use of other, so-called ‘psychotropic medication’ (see British 
18 National Formulary (BNF), Chapter 4, 2016) in the absence of (i) an appropriate mental 
19 health condition; or (ii) a neurological condition, such as epilepsy, for which anti-convulsant 
21 medication is the first-line treatment (NICE, 2016). The medications of interest include 
22 sedatives and anxiolytics (e.g., lorazepam), anti-depressants (e.g., citalopram, fluoxetine), 
23 and anti-convulsants (e.g., sodium valproate, carbamazepine) where these are used as 
24 mood stabilisers rather than to treat epilepsy. 
25 
26 In  the  UK,  the  recent  concerns  about  the  use  of  medication  have  had  two  major 
27 consequences. First, a range of practice guidelines have been developed, aimed primarily at 
28 General Practitioners (GPs) and psychiatrists (NICE guideline NG11, 2015; NICE Guideline 
29 NG54, 2016; NHS England, 2017; Royal College of Psychiatrists, 2016), focusing particularly 
31 on the use of psychotropic medication for the management of perceived behavioural 
32 problems. Importantly, the guidelines emphasise the importance of a multi-disciplinary 
33 approach to managing such behaviour, with medication being considered when (i) 
34 psychological or other interventions alone have not been effective, (ii) when treatment for co- 
35 morbid physical and/or mental health conditions is needed; and/or (iiii) the risk to the service 
36 user or others is high. They also emphasise the importance of reviews (at 6 weeks, 3 
38 months, and every 6 months thereafter, NHS England, 2017) of the benefits of  continuing 
39 medication. 
40 
41 Secondly, our knowledge about patterns of prescribing of psychotropic medications to 
42 people with learning disabilities in the UK has improved considerably (e.g., Deb et al., 2015). 
43 
44 Two recent studies (Glover and Williams, 2015; Sheehan et al., 2015), using General 
45 Practitioner (GP) records, are especially relevant. Both examined medication prescribing 
46 patterns for very large numbers of people with learning disabilities (N >  17,000 in England; 
47 Glover and Williams, 2015 and N > 33,000 across the UK; Sheehan et al., 2015).  The data 
48 are complex: they rely on correct identification of people with learning disabilities; accurate 
49 recording of the rationale for prescribing and ages; the acknowledgment that some 
51 medications are prescribed for more than one reason; that some medicines may be being 
52 prescribed to prevent relapse; and so on. Nevertheless, there are two striking findings: 
53 
54 (i) people with learning disabilities are being prescribed psychotropic medication in 
55 the absence of a condition that would justify its use. Sheehan and his colleagues 
56 found that fewer than a third (29%, N=6,503) of those being prescribed anti- 
58 psychotic medication had a recorded mental health condition (including epilepsy) 
58 
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3 for which such treatment would be appropriate. Similarly, with regard to anti- 
4 depressants, Glover and Williams (2015) suggested that this class of medications 
5 was being prescribed to far more individuals than had a recorded affective 
6 disorder; 
7 
8 (ii) psychotropic medication is being prescribed for the management of behavioural 
9 needs alone. For example, Sheehan et al. (2015) found that more than a third 
10 (35%) of people with recorded behavioural needs were prescribed anti-psychotic 
11 medication despite having no reported mental health or neurological condition for 
12 which such medicine would be appropriate. Indeed, among people with learning 
13 disabilities, taking into account the presence of a diagnosis relating to a 
15 neurodevelopmental, neurological or neurodegenerative condition (autism, 
16 epilepsy, or dementia), those with behavioural needs reported in their GP records 
17 were more than twice as likely as those without to be prescribed anti-psychotic 
18 medication. 
19 
20 
At the least, these findings suggest poor clinical practice. In some cases, they raise concerns 
22 about the violation of the human rights of people with learning disabilities (for example, the 
23 prohibition of discrimination under Article 14 of the, Human Rights Act 1998; see Wadham et 
24 al., 2007). 
25 
26 
These two important studies of GP prescribing will have included, but will not have been 
27 
limited to, individuals who are in contact with specialist community teams for adults with 
29 learning disabilities (CTLDs hereafter). It is rare for medication to be prescribed directly by 
30 CTLDs; instead, psychiatrists in these teams provide advice to GPs, normally in the form of a 
31 medical letter. The aim of the current study was to examine the use of anti-psychotic and 
32 other psychotropic medication by service users one year after their referral to a county-wide 
33 specialist community learning disabilities service for assessment, treatment and/or support 
34 for a mental health and/or behavioural need. In particular, we sought to investigate the extent 
36 to which the use of such medication was based on a recorded condition for which it would be 
37 appropriate. 
38 
39 
Methods 
40 
41 
42 Ethics 
43 Ethical approval for this study was provided by NRES 12/EE/0372. Following the Mental 
44 Capacity Act (England and Wales) 2005 (MCA), there was a presumption that people with 
45 learning disabilities, as well as their care-givers, had the capacity to give or withhold consent 
46 to participation. For individuals who were assessed as lacking the relevant decision-making 
48 capacity, advice about their participation was sought from consultees (s. 30ff, MCA). 
49 
50 Context 
51 This study was undertaken as part of a programme of research investigating the work of five 
52 locality-based CTLDs and, specifically, their work with adults with learning disabilities who 
53 possibly had additional mental health and/or behavioural needs. These CTLDs formed part 
55 of a county-wide service, based in the East of England and, between them, covered both 
56 urban and rural areas, some of which experienced significant deprivation. At the time of  data 
57 collection, all the teams were multi-disciplinary and inter-agency, with: (1) NHS health care 
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3 providers in psychiatry, arts therapies (art and music), clinical psychology, learning disability 
4 nursing, occupational therapy, and speech and language therapy; and (2) local authority 
5 care managers (some of whom were qualified social workers) commissioning and monitoring 
6 social care provision. Further details are provided in Clare et al. (2016). 
7 
8 
9 Participants 
10 There were two groups of participants. First, adults (aged 18 years or more) with learning 
11 disabilities, recruited as soon as possible after being referred to, and accepted by, one or 
12 another of the service’s five specialist community teams (CTLDs) for assessment, treatment 
13 and/or support for a possible mental health and/or behavioural need. All were living in 
15 community settings: on their own, with partners or family members, or with other people with 
16 learning disabilities. There was considerable variation in the extent to which participating 
17 service users received paid or informal social care support. The second group of participants 
18 were care-givers (family members or paid support workers). Where possible, these 
19 individuals were nominated by the participants with learning disabilities as people who knew 
20 them well. 
22 
23 Measures and data collection 
24 The data were collected by practitioner researchers who had previously worked (but with one 
25 exception) no longer worked in the service, and included: 
26 
27 
1. The British Picture Vocabulary Scale – 3rd Ed. (BPVS-III, Dunn et al., 2009). This is a 
29 brief measure of understanding of single words, covering a wide range of ability (from 
30 an age equivalent of 2 years 6 months to 16 y 11 m). It was used to provide a rough 
31 estimate of participants’ intellectual functioning. Participants completed the measure 
32 as soon as possible after recruitment. 
33 2. Relevant ‘diagnoses’. Twelve months after recruitment, participants’ records held by 
34 the relevant CTLD were used by the practitioner researchers to provide information 
36 about the presence or absence of mental health conditions or epilepsy (‘diagnoses’) 
37 for which advice about prescribing psychotropic medication might have been given. 
38 3. The Client Service Receipt Inventory (CSRI, Beecham and Knapp, 2001; Strydom et 
39 al., 2010) was developed for costing interventions. It was used here to collect data 
40 from paid or informal care-givers (and sometimes service users themselves, if they 
41 received only minimal support) about participants’ psychotropic medications in the 
43 three months preceding follow-up, 12 months after recruitment. It was assumed  that, 
44 by  this  time,  any  assessments  and/or  reviews  of  medication  would  have   been 
45 completed by the CTLDs and that advice to GPs about changes in prescribing would 
46 have been provided by the relevant psychiatrist. As far as possible, we checked 
47 service  users’  CTLD  records  to  find  evidence  of  such  advice.  The  reported 
49 medications were classified and the reported dosages checked. Chapter 4 of the 
50 British National Formulary (BNF; https://www.bnf.org/products/bnf-online), which 
51 provides the most up-to-date guidance for psychiatrists, pharmacists, GPs and others 
52 about psychotropic medication, was used. 
53 
54 
Results 
56 Relevant data were available for 54 individuals from the 322 relevant referrals made to the 
57 CTLDs. Initially, consent (or favourable advice from a consultee) was given by 80 service 
58 users; 189 did not respond; 53 were excluded because they did not consent (or their 
58 
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3 consultee’s advice regarding participation was unfavourable). Twelve months later, three of 
4 the participants had died; another six had withdrawn; and 17 people were either 
5 uncontactable (e.g., they had moved to a different county) or it was not possible to obtain 
6 valid data (e.g., neither the care-giver nor the service user was able to provide information). 
7 
8 
9 Service user characteristics at referral 
10 The 54 participants (28 men and 26 women) were overwhelmingly from white British 
11 backgrounds and ranged in age from 18-67 years (mean age: 39 years; s.d. 15). Fifteen 
12 people, all with what appeared to be severe learning disabilities, were unable to complete 
13 the measure of understanding of single words (BPVS). The median tested raw BPVS score 
15 of the remaining 39 was 104 (range: 4-165; age equivalent: 6 years 10 months; 95% CI: 6 y 
16 2 m to 7 y 5m), suggesting that the sample, though small, was diverse. 
17 
18 Prescription of psychotropic medication 12 months after referral 
19 
20 
What were the service users’ assessed ‘diagnoses’? 
21 
All 54 participants met the necessary access criteria for specialist health services for people 
23 with learning disabilities. Seventeen participants had a current or past, (for three individuals) 
24 recorded diagnosis of a mental health condition, and a further seven had a diagnosis of 
25 epilepsy (two of whom had also been diagnosed with a mental health need). Together,  these 
26 24  people  comprised  44%  of  the  sample.  Psychotropic  medication  could  have  been 
27 appropriate for all of them. A further nine (17%) participants had a behavioural need on its 
28 
29 own or in conjunction with another neurodevelopmental (autism and/or ADHD) or 
30 degenerative condition, while another six (11%) had a neurodevelopmental or degenerative 
31 condition only. The remaining 15 (28%) had learning disabilities but were not recorded as 
32 having any other condition for which psychotropic medication might be appropriate. 
33 
34 
What psychotropic medications were recorded? 
36 Twelve months after referral, it  appeared that  41 (76%)  of the 54  participants were using 
37 regular psychotropic medications, of whom about a quarter (24%, n=10) were also taking 
38 PRN medication. One additional person was using PRN medication on its own. Table 1 
39 shows the number of participants using each medication, categorised according to Ch. 4 of 
40 the British National Formulary, 2016. 
41 
42 
43 
44 
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Table 1: The use of different psychotropic medications (categories from Chapter 4, 
5 
6 British National Formulary, 2016) by participants (numbers in brackets indicate the 
7 number of participants using each medication) 
8 
9    
10 BNF categorisation Medication 
11    
12 4.1 All hypnotics and anxiolytics 
13 4.1.1 Hypnotics 
14 4.1.2 Anxiolytics 
 
Melatonin (2) 
Lorazepam (4)1, Diazepam (1)1 
15    
16 4.2 All antipsychotics 
17 4.2.1 Antipsychotic Drugs 
18 
19 1
st 
Generation 
20 2
nd Generation 
21 
22 
23 4.2.2 Antipsychotic depot injections 
24 4.2.3 Drugs used for mania and hypomania 
25 
 
 
Sulpiride (1), Chlorpromazine Hydrochloride 
(1) 
Aripiprazole (2), Quetiapine (2) Olanzapine, 
(3), Risperidone (8) 
Haloperidol (1) 
Lithium carbonate (2) 
26    
27 4.3 All antidepressants 
28 4.3.1 Tricyclic and related antidepressant 
29 drugs 
31 4.3.3 Selective serotonin reuptake inhibitors 
32 4.3.4 Other antidepressant drugs 
33 
34 4.8 All antiepileptic drugs 
35 4.8.1 Control of the epilepsies 
36 
37 
38 
39 
40 
4.8.2 Drugs used in status epilepticus 
42 
43 
44 
45 
 
Amitriptyline (1) 
Sertraline (9), Citalopram (8), Fluoxetine (6) 
Mirtazapine (2), Venlafaxine (1), 
 
 
Sodium valproate(3), Levetiracetam (3), 
Topiramate (3), Carbamazepine (2), Epilim 
chrono (2), Phenobarbital (1), Phenytoin (1), 
Lamotrigine (4) 
Clobazam (1) Zonisamide (1) , Clonazepam 
(1), Buccal midazolam (2), Lorazepam (2)2, 
Diazepam (1)
2
 
46 
1 Both medications were only to be used as required (PRN) rather than regularly; 2 Where 
47 these ‘as required’ medications were given to people with a diagnosis of epilepsy, it was 
48 assumed that they were being used to treat status epilepticus (as recommended by NICE, 
50 2016). 
51 
52 
53 The pattern of psychotropic medication use of the participants appeared unexceptional: none 
54 of  those  with  a mental health condition (such as a  bipolar  disorder) and/or epilepsy   was 
55 receiving medication that, when checked against the British National Formulary (BNF, 2016), 
56 could be considered inappropriate. The reported dosages of each medication were also 
57 checked against the BNF recommendations: not a single one was recorded as being used at 
58 
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3 higher than the recommended dose. Polypharmacy (prescribing more than one medication 
4 to treat co-existing conditions) was most evident among those with a diagnosis of epilepsy. 
5 Where service users were taking more than one medication in the same class, it was not 
6 possible to ascertain whether this was long-term or was a snapshot of a process of change. 
7 
8 
9 What medications were being used by those with no recorded mental health or 
10 neurological condition? 
11 The use of psychotropic medications has been of most concern when prescribed in the 
12 absence of an appropriate mental health need or neurological condition such as epilepsy. 
13 For this reason, we examined their use by the 30 participants with no additional current or 
15 past  diagnosis:  that  is, only those  with  an  additional developmental  (autism,  ADHD) or 
16 degenerative (dementia) condition on its own; or only a behavioural need with or without an 
17 additional developmental or degenerative condition. Table 2 shows the data. 
18 
19 
20 
Table 2. Psychotropic medications recorded by participants with no current or past 
22 additional conditions, an additional developmental or degenerative condition only, or 
23 a behavioural need with or without an additional developmental condition 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 More than half (53%, n= 8) of the fifteen participants with no recorded additional diagnosis, 
45 apart from a learning disability, were reported to be using regular psychotropic medication 
46 (mainly anti-depressants). Two-thirds of those with an additional developmental or 
47 degenerative condition (67%) or behavioural need (67%) also seemed to be receiving 
48 psychotropic medication. Only participants with an additional behavioural need were using 
49 as required medication. 
50 
51 
52 
53 Discussion 
54 
55 
56 In order to complement recent studies using very large samples of adults selected from a 
57 large database of GP records (Sheehan et al., 2015) or because they were entitled to annual 
58 health checks by GPs (Glover and Williams, 2015), we carried out a small descriptive study 
Additional conditions No. of 
participants 
No. with 
recorded 
psychotropic 
medications 
No. of 
different 
psychotropic 
medications 
No. with 
recorded 
regular 
psychotropic 
medication 
No. with 
recorded as 
required 
(PRN) 
psychotropic 
medications 
None current or past 15 8 1-2 8 0 
Autism/ADHD/dementia 
only 
6 4 1 4 0 
Behavioural need (with or 
without   
autism/ADHD/dementia) 
only 
9 6 1-3 5 5 
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3 in a county-wide service comprising five locality-based specialist community teams (CTLDs). 
4 The aim was to document participants’ recorded use of psychotropic medication, that is, 
5 medication that affects a person’s mental functioning through action on the Central Nervous 
6 System, twelve months after they had been accepted by the study for assessment, treatment 
7 
8 and/or support for a putative or diagnosed mental health and/or behavioural need. 
9 
10 The available data indicated that more than three-quarters (77%, n=42) of the sample of 54 
11 participants, were using regular and/or as required (PRN) psychotropic medication. Of these, 
12 just over a half (57%, n=24) had recorded mental health or neurological conditions that 
13 would, in principle, have justified the use of these kinds of medication and, indeed, could 
15 have been life-saving. In contrast with the findings of Glover and Williams (2015), no regular 
16 or as required medication was being used above its recommended dose. 
17 
18 The overall findings were consistent with those of the two previous, very large, studies 
19 (Glover and Williams, 2015; Sheehan et al., 2015). There was a discrepancy between the 
20 number of participants using psychotropic medication and the presence of a recorded mental 
22 health condition or epilepsy. There were 18 participants (33% of the whole sample) who 
23 were reported as using one or more psychotropic medications, either regularly and/or as 
24 required (PRN), in the apparent absence of any condition that would have justified its/their 
25 use. There was, therefore, evidence that psychotropic medication was ‘overused’  (Sheehan 
26 
et al., 2015, p. 1). 
27 
28 
29 The study reported here had a number of limitations: the sample was small, and we make no 
30 claim that it was representative even of the service users seen by the five CTLDs in the 
31 learning disability service. There were particular difficulties in recruiting men and women who 
32 needed permission from a consultee (a family member) to participate but were not living with 
33 their families; many paid support  workers  were reluctant  to  take  on this  role. For service 
34 users  with  mild  learning  disabilities,  often  with  very  limited  support,  there  were other 
36 difficulties: in a few cases, we were reliant on self-reports although, where possible, the 
37 practitioner researchers asked to see the participants’ medication. In contrast with the two 
38 large studies (Glover and Williams, 2015; Sheehan et al., 2015), we had no access to 
39 primary care records so we did not know the extent to which advice about changes in 
40 medication had been given to GPs following psychiatric reviews, or accepted by them. 
41 Strikingly, nor was it even possible to locate all the relevant information as we were unable to 
43 find many of the psychiatrists’ letters to primary care services. It is unlikely that these letters 
44 were not written. Moreover, at least some of them may have contained information about 
45 additional conditions relevant to those participants apparently using psychotropic medication 
46 without an appropriate justification. These problems in locating medical letters were 
47 indicative of the challenges that made it difficult, even for practitioner researchers who had 
49 worked, or were working, in the teams, to reconstruct the ‘story’ of the responses to referrals. 
50 While perhaps exacerbated by staff vacancies around the time of the study, so that relevant 
51 documents were not always filed, there were systemic barriers to formal knowledge 
52 exchange. These included different information technology (IT) systems for psychiatry vs 
53 other NHS health care practitioners; online systems for local authority care managers and 
54 psychiatrists vs. paper for other NHS team members; separate physical locations for 
56 different members of the same team (see Farrington et al., 2015). Instead, as Farrington and 
57 his colleagues noted, there was a reliance on informal solutions (‘corridor conversations’) 
58 that appeared arbitrary and were unsustainable. The clinical governance, IT and other issues 
59 
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3 that compromise formal knowledge exchange in this (and, anecdotally, other) specialist 
4 community services for people with learning disabilities need urgently to be resolved so that 
5 relevant documents are available for review by team members and by others concerned with 
6 service users’ well-being. 
7 
8 
9 The study raised other issues. As the NICE guidelines emphasise (e.g., NICE, 2015,  2016), 
10 there is no alternative to a multi-disciplinary approach to mental health and/or behavioural 
11 needs. Data collection for this study was carried out before these guidelines were available 
12 and practice in this service has since changed. It is still worth, however, asking why 
13 psychiatrists might still provide advice about using psychotropic medication apparently in the 
15 absence of a diagnosed condition for which it would be appropriate. Any perceived ‘crisis’ in 
16 a community setting is known to have significant adverse impacts on the service user 
17 involved, any victims, and on their family and paid care-givers; it may also raise safeguarding 
18 concerns. ‘Crisis’ referrals to psychiatrists often demand a rapid response, but the 
19 immediately available options may be very limited and none may clearly be in a service 
20 user’s best interests: admission to a (not always local) in-patient service; increased use of 
22 physical  restraint  and/or  calling  the  police  though  the  person  him  or  herself  cannot 
23 meaningfully  be  involved  in  the  criminal  justice  system;  or  advising  the prescription of 
24 medication, particularly short-term ‘as required’ sedative medication, until the situation can 
25 be discussed with other members of the CTLD. 
26 
27 
‘Crisis’ demands to ‘do something’ are not unique to psychiatry among medical disciplines, 
29 and perhaps reflect more general expectations regarding the prescription of medication. An 
30 analogy may be drawn with the complex dynamics underlying the (over-) prescribing of 
31 antibiotics (Fleming-Dutra et al., 2016) and the increasing, and very serious, risks of 
32 resistance (NICE, 2017). Despite the well-known risks, patients continue to seek 
33 prescriptions for antibiotics when they are not clinically justified, and GPs continue to 
34 respond. It  has been  argued that medical practitioners face particularly intense  pressures 
36 when there are uncertainties about the diagnosis and a ‘wait and see’ approach may have 
37 very adverse consequences for the patient and their care-givers (for example, otitis media in 
38 children, Moro et al., 2009) and/or may lead to litigation (see Woon and Fisher, 2016). For 
39 people with learning disabilities, for whom the reliable diagnosis of mental health conditions 
40 remains problematic (Buckles et al., 2013), the prescription of psychotropic medication may 
41 appear to be the least risky strategy. Some support for this account comes from Wastell et 
43 al. (2016): in an exploration of the reasons provided by psychologists, nurses, and 
44 psychiatrists for prescribing psychotropic medication for behavioural needs, tensions were 
45 identified between good clinical practice (safe, evidence-based and ethical), risk, and 
46 contextual factors (such as conditions in a service user’s social care  provision). These 
47 studies highlight the importance, once individuals are taking psychotropic, including anti- 
49 psychotic, medication of carrying out reviews, including multi-disciplinary reviews (NICE 
50 guidelines, 2015, 2016) to ensure that any medicines are of benefit. 
51 
52 The discrepancies between the prescription of psychotropic, including anti-psychotic, 
53 medication and the presence of diagnosed conditions for which such medication would be 
54 appropriate have now been convincingly documented; there remains, however, much more 
56 for CTLDs to do. First, as noted, there is a need to develop knowledge exchange systems 
57 that reflect and promote the multi-disciplinary and inter-agency collaboration that is a feature 
58 of community learning disability services. Secondly, clinical decision-making of all kinds 
58 
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3 depends on the collection of reliable and valid data. Relevant data collection is most likely to 
4 take place when it makes limited demands on care-givers, reflects their input and so can be 
5 ‘owned’ by them, and provides rapid or even immediate feedback. Investment in apps, such 
6 as Lincus (www.innovationgagencyexchange.org.uk) and their development to provide more 
7 
8 sophisticated information is required. Data collection also becomes much more feasible 
9 where CTLDs have established working relationships with social care providers (including 
10 families)  in the relevant geographical locality.  In addition,  such  relationships enable team 
11 members  to  understand  not  only  the  immediate  environment  in  which  referrals  for 
12 assessment, treatment and support of service users’ mental health and/or behavioural needs 
13 take place but also the broader local context (for example, the availability of suitable staffing, 
15 opportunities for social inclusion for service users). The pressure upon CTLDs to adopt out- 
16 patient clinic models to save resources is, we believe, short-sighted and highly regrettable, in 
17 part because it is more likely to lead to a requirement for crisis management and the 
18 perpetuation of inappropriate prescribing. 
19 
20 
Thirdly, more complex formulations of service users’ needs are required to guide decision- 
22 making about medication and other interventions and establish person-centred outcomes. 
23 Increasingly, such formulations should include neurobiological as well as other relevant 
24 information, and should be produced by CTLDs as a team, rather than by different 
25 disciplines, in collaboration with families and other care-givers (and with service users, as far 
26 as possible) and other involved NHS, LA and third sector agencies. The production of such 
27 integrated formulations is a key part of establishing working relationships between CTLDs, 
29 service users and those who care for or about them. The complexity of this task should not 
30 be underestimated; but that does not mean the effort should not be made. 
31 
32 There are now many studies that indicate that psychotropic medication is prescribed to 
33 manage the perceived behavioural needs of people with learning disabilities in the absence 
34 of a clear justification such as a relevant mental health or neurological condition. We argue 
36 that prescription of these medications may be a marker of the difficulties that CTLDs often 
37 experience in providing comprehensive intervention and management plans that include 
38 psychotropic medication when it is justified, underpinned by detailed assessments and 
39 integrated formulations. Investment in developments that promote multi-disciplinary and 
40 inter-agency working is needed to promote ‘good practice’ by CTLDs in responding  to 
41 referrals for mental health and/or behavioural needs. 
43 
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